162 related articles for article (PubMed ID: 22280534)
1. Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Yamada T; Sawada M; Takahashi T; Yamada T; Seishima M; Moriwaki H; Takami T
Leuk Lymphoma; 2012 Aug; 53(8):1494-500. PubMed ID: 22280534
[TBL] [Abstract][Full Text] [Related]
2. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
4. Elevated soluble CD 27 levels (TNF-receptor) may predict survival in diffuse large B-cell lymphoma--revisiting "the super- family " saga.
Tadmor T; Polliack A
Leuk Lymphoma; 2012 Aug; 53(8):1439-40. PubMed ID: 22335528
[No Abstract] [Full Text] [Related]
5. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
8. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
9. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
10. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
13. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
Qiu H; Li J; Feng Z; Yuan J; Lu J; Hu X; Gao L; Lv S; Yang J; Chen L
Clin Exp Pharmacol Physiol; 2016 Sep; 43(9):795-801. PubMed ID: 27247195
[TBL] [Abstract][Full Text] [Related]
14. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
Yamamoto W; Nakamura N; Tomita N; Takeuchi K; Ishii Y; Takahashi H; Watanabe R; Takasaki H; Motomura S; Kobayashi S; Yokose T; Ishigatsubo Y; Sakai R
Leuk Lymphoma; 2014 Dec; 55(12):2721-7. PubMed ID: 24528218
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
18. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
